Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients

Journal of Clinical Pharmacology

Volumn 55, Issue 8, 2015, Pages 899-908

  Chung, Eun Kyoung ^a   Cheatham, S Christian ^b   Fleming, Megan R ^c   Healy, Daniel P ^d   Shea, Katherine M ^e   Kays, Michael B ^f  

^a Kyung Hee University   (South Korea)

^b Franciscan St Francis Cancer Center   (United States)

^c METHODIST DALLAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^e University Medical Center Brackenridge   (United States)

^f PURDUE UNIVERSITY   (United States)

Author keywords

Monte Carlo simulation; NONMEM; obesity; piperacillin; tazobactam

Indexed keywords

PIPERACILLIN; TAZOBACTAM; ANTIINFECTIVE AGENT; CREATININE; PENICILLANIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBESITY; STEADY STATE; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPUTER SIMULATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; BODY WEIGHT; COMPUTER SIMULATION; CREATININE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OBESITY; PENICILLANIC ACID; PIPERACILLIN;

EID: 84936118320     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.505     Document Type: Article

References (40)

1. World Health Organization. Obesity and overweight. Geneva, Switzerland: WHO; 2012. Fact sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/en. Accessed June 22, 2014.
2. Stevens GA, Singh GM, Lu Y, et al., National regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012; 10: 22.
3. Ogden CL, Carroll MD, Kit BK, Flegal KM., Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311: 806-814.
4. Public Health England. Adult obesity: morbid obesity. http://www.noo.org.uk/NOO-about-obesity/morbid-obesity. Accessed June 22, 2014.
5. Janson B, Thursky K., Dosing of antibiotics in obesity. CurrOpin Infect Dis. 2012; 25: 634-649.
6. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG,. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007; 5: 365-383.
7. Lodise TP, Lomaestro BM, Drusano GL., Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26: 1320-1332.
8. Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN., Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994; 38: 2351-2356.
9. Lister PD, Prevan AM, Sanders CC., Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob Agents Chemother. 1997; 41: 721-727.
10. VanScoy B, Mendes RE, Nicasio AM, et al., Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013; 57: 2809-2814.
11. Zakrison TL, Hille DA, Namias N., Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt). 2012; 13: 38-42.
12. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB., Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents. 2009; 34: 429-433.
13. Cheatham SC, Fleming MR, Healy DP, et al., Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents. 2013; 41: 52-56.
14. Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA., Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother. 1997; 41: 2511-2517.
15. Auclair B, Ducharme MP., Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Antimicrob Agents Chemother. 1999; 43: 1465-1468.
16. Felton TW, Hope WW, Lomaestro BM, et al., Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother. 2012; 56: 4087-4094.
17. Byon W, Smith MK, Chan P, et al., Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013; 2: e51.
18. Zosyn® [package insert]. Philadelphia, PA: Pfizer Injectables; 2013.
19. Tam VH, Preston SL, Drusano GL., Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Pharmacotherapy. 2003; 23: 1545-1549.
20. Vinks AA, Den Hollander JG, Overbeek SE, Jelliffee RW, Mouton JW., Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother. 2003; 47: 541-547.
21. Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holfod NH., Nonlinear pharmacokinetics of piperacillin in healthy volunteers-implications for optimal dosage regimens. Br J Clin Pharmacol. 2010; 70: 682-693.
22. Landersdorfer CB, Bulitta JB, Kirkpatrick CM, et al., Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother. 2012; 56: 5715-5723.
23. Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL., Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother. 2004; 48: 4718-4724.
24. Bulitta JB, Duffull SB, Kinzig-Schippers M, et al., Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2007; 51: 2497-2507.
25. Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J., First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010; 35: 156-163.
26. Jeon S, Han S, Lee J, et al., Population pharmacokinetic analysis of piperacillin in burn patients. Antimicrob Agents Chemother. 2014; 58: 3744-3751.
27. Stein GE, Kulhanek G, Smith CL, et al., Pharmacokinetics and Monte Carlo simulations of doripenem in patients with febrile neutropenia. Ann Pharmacother. 2012; 46: 1281-1286.
28. Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP., Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J AntimicrobChemother. 2014; 69: 176-179.
29. Jain R, Chung SM, Jain L, et al., Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011; 90: 77-89.
30. Hanley MJ, Abernethy DR, Greenblatt DJ., Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010; 49: 71-87.
31. Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van der Anker JN, Knibble CAJ., Impact of obesity on drug metabolism and elimination in adults and children. ClinPharmacokinet 2012; 51: 277-304.
32. Deman H, Verhaegen J, Willems L, Spriet I., Dosing of piperacillin/tazobactam in a morbidly obese patient. J Antimicrob Chemother. 2012; 67: 782-783.
33. Newman D, Scheetz MH, Adeyemi OA, et al., Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother. 2007; 41: 1734-1739.
34. Hites M, Taccone FS, Wolff F, et al., Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013; 57: 708-715.
35. Sturm AW, Allen N, Rafferty KD, et al., Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy. 2014; 34: 28-35.
36. Dellit TH, Owens RC, McGowan JE, et al., Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44: 159-177.
37. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22. Wayne, PA: CLSI; 2012.
38. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0; 2015. http://www.eucast.org.
39. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website. http://www.eucast.org. Accessed January 22, 2015.
40. Martinez MN, Papich MG, Drusano GL,. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012; 56: 2795-2805.